Physician profile
Robert Hendley
NPI 1457354698
$8,941.57
in general payments reported to CMS, 2019-2025
38 companies · $536 in 2025
The $536 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,173 · 2020: $676 · 2021: $1,385 · 2022: $1,275 · 2023: $2,317 · 2024: $1,580 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,754 · Travel and Lodging: $638 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,754.17 |
| Travel and Lodging | $637.89 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,056.11 | 2019-2025 | Watchman Access System, Watchman Flx, Resonate El Icd Vr |
| Novartis Pharmaceuticals Corporation | $1,036.14 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $723.42 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $607.87 | 2019-2025 | Farxiga |
| Abbott Laboratories | $483.38 | 2021-2024 | Amplatzer Amulet, Mitraclip |
| Pfizer INC. | $464.17 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $456.23 | 2019-2024 | Xarelto |
| Edwards Lifesciences Corporation | $419.08 | 2021-2024 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $397.69 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.66 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $267.56 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $242.45 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $237.33 | 2021-2023 | Verquvo |
| Cvrx, INC. | $227.38 | 2023-2025 | Barostim Neo System |
| Amgen INC. | $223.56 | 2019-2025 | Repatha, Repatha |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hendley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.